Skip to main navigation
Skip to search
Skip to main content
Aston Research Explorer Home
Help & FAQ
Home
Research units
Profiles
Research output
Datasets
Student theses
Activities
Press/Media
Prizes
Equipment
Search by expertise, name or affiliation
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
School of Biosciences
College of Health and Life Sciences
Aston Research Centre for Health in Ageing
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Alogliptin after acute coronary syndrome in patients with type 2 diabetes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Type 2 Diabetic Patients
100%
Acute Coronary Syndrome
100%
Alogliptin
100%
Placebo
85%
Antihyperglycemic
28%
Dipeptidyl peptidase-4 (DPP-4)
28%
Hazard Ratio
28%
Drug Therapy
14%
Regulatory Agencies
14%
Cardiovascular Risk
14%
Non-inferiority Trial
14%
Hypoglycemia
14%
Safety Profile
14%
Cardiovascular Safety
14%
Cardiovascular Drugs
14%
Comprehensive Evaluation
14%
Pancreatitis
14%
Cardiovascular Outcomes
14%
Antidiabetic Therapy
14%
Non-inferiority
14%
Hospitalization
14%
New Antidiabetic Drugs
14%
Acute Myocardial Infarction
14%
Stable Angina
14%
Major Adverse Cardiovascular Events
14%
Repeated Confidence Intervals
14%
Development Centre
14%
New Inhibitors
14%
Noninferiority Margin
14%
Nonfatal Myocardial Infarction
14%
Glycated Hemoglobin Levels
14%
Upper Boundary
14%
Dialysis Initiation
14%
Nonfatal Stroke
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
100%
Alogliptin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
85%
Malignant Neoplasm
14%
Pharmacotherapy
14%
Antidiabetic Agent
14%
Dipeptidyl Peptidase IV
14%
Hypoglycemia
14%
Heart Infarction
14%
Cardiovascular Risk
14%
Glycosylated Hemoglobin
14%
Cardiovascular Agent
14%
Dipeptidyl Peptidase IV Inhibitor
14%
Pancreatitis
14%
Cerebrovascular Accident
14%
Acute Heart Infarction
14%
Unstable Angina Pectoris
14%
Noninferiority Trial
14%
Cardiovascular Disease
14%